Angeion Corporation to Present at the
Roth
Capital Partners 19th Annual OC Conference
SAINT PAUL, Minn. (February 19, 2007) — Angeion Corporation
(NASDAQ: ANGN) today announced that Rodney Young, the Company’s
President and Chief Executive Officer, will be presenting at the Roth
Capital Partners 19th Annual OC Conference, to be held February 19-22,
2007, at the Ritz Carlton in Laguna Niguel, California.
Angeion’s investor presentation is scheduled for Wednesday, February 21,
2007 at 2:00 p.m. PT.
About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation
in December 1999. Medical Graphics develops, manufactures and
markets non-invasive cardiorespiratory diagnostic systems that are
sold under the MedGraphics (www.medgraphics.com)
and New Leaf (www.newleaffitness.com)
brand and trade names. These cardiorespiratory diagnostic systems have
a wide range of applications in healthcare as well as health and fitness. The
Company’s products are sold internationally through distributors and in
the United States through a direct sales force that targets heart and lung specialists
located in hospitals, university-based medical centers, medical clinics and physicians’ offices,
pharmaceutical companies, medical device manufacturers, clinical research organizations,
health and fitness clubs, personal training studios, and other exercise facilities. For
more information about Angeion, visit www.angeion.com.
The discussion above contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These statements
by their nature involve substantial risks and uncertainties. Our results
may differ materially depending on a variety of factors, including: (i) Our ability
to successfully operate our business including our ability to develop, improve,
and update our cardiorespiratory diagnostic products, (ii) Our ability to effectively
manufacture and ship our products in anticipated required quantities to meet
customer demands, (iii) Our ability to successfully defend the Company from product
liability claims related to our cardiorespiratory diagnostic products and claims
associated with our prior cardiac stimulation products, (iv) Our ability to protect
our intellectual property, (v) Our ability to develop and maintain an effective
system of internal controls and procedures and disclosure controls and procedures,
and (vi) Our dependence on third-party vendors. Additional information
with respect to the risks and uncertainties faced by the Company may be found
in, and any prior discussion is qualified in its entirety by, the other risk
factors that are described from time to time in Angeion's Securities and Exchange
Commission reports, including but not limited to the Annual Report on Form 10-KSB
for the year ended October 31, 2006, and subsequently filed reports.
###
|
